BACKGROUND: Numerous studies have shown that in addition to angio/lymphangiogenesis, the VEGF family is involved in other cellular actions. We have recently reported that enhanced VEGF-C and VEGFR-3 in the infarcted rat myocardium, suggesting the paracrine/autocrine function of VEGF-C on cardiac remodeling. The current study was designed to test the hypothesis that VEGF-C regulates cardiomyocyte growth and survival in the infarcted myocardium. METHODS AND RESULTS: Gene profiling and VEGFR-3 expression of cardiomyocytes were assessed by laser capture microdissection/microarray and immunohistochemistry in the normal and infarcted myocardium. The effect of VEGF-C on myocyte hypertrophy and apoptosis during normoxia and hypoxia was detected by RT-PCR and western blotting in cultured rat neonatal cardiomyocytes. VEGFR-3 was minimally expressed in cardiomyocytes of the normal and noninfarcted myocardium, while markedly elevated in the surviving cardiomyocytes of the infarcted myocardium and border zone. Genes altered in the surviving cardiomyocytes were associated with the networks regulating cellular growth and survival. VEGF-C significantly increased the expression of atrial natriuretic factor (ANP), brain natriuretic factor (BNP), and β-myosin heavy chain (MHC), markers of hypertrophy, in neonatal cardiomyocytes. Hypoxia caused neonatal cardiomyocyte atrophy, which was prevented by VEGF-C treatment. Hypoxia significantly enhanced apoptotic mediators, including cleaved caspase 3, 8, and 9, and Bax in neonatal cardiomyocytes, which were abolished by VEGF-C treatment. CONCLUSION: Our findings indicate that VEGF-C/VEGFR-3 pathway exerts a beneficial role in the infarcted myocardium by promoting compensatory cardiomyocyte hypertrophy and survival.
BACKGROUND: Numerous studies have shown that in addition to angio/lymphangiogenesis, the VEGF family is involved in other cellular actions. We have recently reported that enhanced VEGF-C and VEGFR-3 in the infarctedrat myocardium, suggesting the paracrine/autocrine function of VEGF-C on cardiac remodeling. The current study was designed to test the hypothesis that VEGF-C regulates cardiomyocyte growth and survival in the infarcted myocardium. METHODS AND RESULTS: Gene profiling and VEGFR-3 expression of cardiomyocytes were assessed by laser capture microdissection/microarray and immunohistochemistry in the normal and infarcted myocardium. The effect of VEGF-C on myocyte hypertrophy and apoptosis during normoxia and hypoxia was detected by RT-PCR and western blotting in cultured rat neonatal cardiomyocytes. VEGFR-3 was minimally expressed in cardiomyocytes of the normal and noninfarcted myocardium, while markedly elevated in the surviving cardiomyocytes of the infarcted myocardium and border zone. Genes altered in the surviving cardiomyocytes were associated with the networks regulating cellular growth and survival. VEGF-C significantly increased the expression of atrial natriuretic factor (ANP), brain natriuretic factor (BNP), and β-myosin heavy chain (MHC), markers of hypertrophy, in neonatal cardiomyocytes. Hypoxia caused neonatal cardiomyocyte atrophy, which was prevented by VEGF-C treatment. Hypoxia significantly enhanced apoptotic mediators, including cleaved caspase 3, 8, and 9, and Bax in neonatal cardiomyocytes, which were abolished by VEGF-C treatment. CONCLUSION: Our findings indicate that VEGF-C/VEGFR-3 pathway exerts a beneficial role in the infarcted myocardium by promoting compensatory cardiomyocyte hypertrophy and survival.
Authors: Marcos F Minicucci; Paula S Azevedo; Bertha F Polegato; Sergio A R Paiva; Leonardo A M Zornoff Journal: Clin Cardiol Date: 2011-06-17 Impact factor: 2.882
Authors: Zhi-Qing Zhao; Cullen D Morris; Jason M Budde; Ning-Ping Wang; Satoshi Muraki; He-Ying Sun; Robert A Guyton Journal: Cardiovasc Res Date: 2003-07-01 Impact factor: 10.787
Authors: K Takenouchi; B Shrestha; M Yamakuchi; N Yoshinaga; N Arimura; H Kawaguchi; T Nagasato; R Feil; K Kawahara; T Sakamoto; I Maruyama; T Hashiguchi Journal: Exp Clin Endocrinol Diabetes Date: 2014-05-16 Impact factor: 2.949
Authors: Jian Wu; Dorothy N Kakoola; Nataliya I Lenchik; Dominic M Desiderio; Dana R Marshall; Ivan C Gerling Journal: PLoS One Date: 2012-10-11 Impact factor: 3.240
Authors: Dakshnapriya Balasubbramanian; Gaurav Baranwal; Mary-Catherine C Clark; Bethany L Goodlett; Brett M Mitchell; Joseph M Rutkowski Journal: J Hypertens Date: 2020-05 Impact factor: 4.776
Authors: Radek Pudil; Martina Vasatova; Alena Fucikova; Helena Rehulkova; Pavel Rehulka; Vladimir Palicka; Jiri Stulik Journal: Biomed Res Int Date: 2015-12-30 Impact factor: 3.411